Paying user area
Try for free
Merck & Co. Inc. pages available for free this week:
- Balance Sheet: Assets
- Cash Flow Statement
- Common-Size Income Statement
- Common-Size Balance Sheet: Assets
- Analysis of Short-term (Operating) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value (EV)
- Dividend Discount Model (DDM)
- Net Profit Margin since 2005
- Return on Equity (ROE) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Merck & Co. Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Inventory Disclosure
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
The data exhibits several notable trends in inventory composition and valuation over the period from 2020 to 2024.
- Finished Goods
- The value of finished goods shows a slight decline from 1963 million USD in 2020 to 1747 million USD in 2021, followed by a gradual recovery in subsequent years, reaching 2022 million USD by 2024. This indicates a stabilization and modest growth in finished goods inventory after an initial drop.
- Raw Materials and Work in Process
- A continuous upward trend is evident, with values increasing steadily from 6420 million USD in 2020 to 8831 million USD by 2024. This growth suggests expanding investment in production inputs and partially completed goods over the years.
- Supplies
- Values for supplies also rise from 206 million USD in 2020 to 289 million USD in 2024, reflecting an increase albeit at a smaller scale compared to raw materials and work in process.
- Inventories (Approximates Current Cost)
- Inventories measured approximately at current cost demonstrate a general increase from 8589 million USD in 2020 to 11142 million USD in 2024. This upward movement aligns with the rising trend in raw materials and supplies, signifying an overall growth in inventory holdings.
- Increase (Decrease) to LIFO Costs
- This item shows increasingly negative values, moving from -82 million USD in 2020 to -840 million USD in 2024, indicating a significant decrease. The deeper negative values suggest adjustments reflecting declining LIFO inventory costs or perhaps shifting price levels influencing inventory valuation downward over time.
- Inventories (Total)
- The total inventories show a fluctuating pattern, with an initial decrease from 8507 million USD in 2020 to 8147 million USD in 2021, followed by a recovery and growth to 10302 million USD by 2024, consistent with trends in approximated current cost inventories.
- Less: Inventories Recognized as Other Assets
- The deduction for inventories classified as other assets increases in magnitude from -2197 million USD in 2020 to -4193 million USD in 2024. This growing subtraction indicates a larger portion of inventory is being classified outside the main inventory accounts, which could impact inventory liquidity and valuation presentation.
- Inventories Excluding Inventories Classified in Other Assets
- When excluding inventories recognized as other assets, the net inventory value declines from 6310 million USD in 2020 to 6109 million USD in 2024, with a low point at 5911 million USD in 2022. This suggests that while total inventories are increasing, the core inventory available within main categories has remained relatively stable or slightly decreased in recent years.
In summary, total inventory investment appears to be growing primarily due to higher holdings in raw materials and work in process. However, the decreasing LIFO costs and a growing classification of inventories as other assets suggest conservative valuation adjustments and possible reclassification affecting reported inventory figures. The stability in finished goods and supplies alongside fluctuating core inventory values highlights a nuanced inventory management approach that balances production inputs with finished product levels.
Adjustment to Inventory: Conversion from LIFO to FIFO
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
Merck & Co. Inc. inventory value on Dec 31, 2024 would be $11,142) (in millions) if the FIFO inventory method was used instead of LIFO. Merck & Co. Inc. inventories, valued on a LIFO basis, on Dec 31, 2024 were $10,302). Merck & Co. Inc. inventories would have been $840) higher than reported on Dec 31, 2024 if the FIFO method had been used instead.
The analysis of the financial data reveals notable trends across the reported and inventory LIFO reserve adjusted values for the periods ending December 31, 2020 through 2024.
- Inventories
- Reported inventories showed a generally upward trend, increasing from 8,507 million USD in 2020 to 10,302 million USD in 2024, with a slight dip in 2021. Adjusted inventories, which account for inventory LIFO reserve adjustments, followed a similar increasing trajectory, starting at 8,589 million USD in 2020 and rising steadily to 11,142 million USD in 2024. The adjustment consistently added value to reported inventories, reflecting the impact of the LIFO reserve on inventory valuation.
- Current Assets
- Reported current assets increased from 27,764 million USD in 2020 to 38,782 million USD in 2024, displaying year-over-year growth except for a decline in 2023. Adjusted current assets were marginally higher than reported current assets in each year, starting from 27,846 million USD in 2020 and reaching 39,622 million USD in 2024, demonstrating steady growth with a similar pattern of a dip in 2023 followed by recovery.
- Total Assets
- Reported total assets increased overall from 91,588 million USD in 2020 to 117,106 million USD in 2024, although the growth rate slowed in 2023 with a slight decrease. Adjusted total assets mirrored this trend, consistently exceeding reported figures by a small margin due to the LIFO reserve adjustment, moving from 91,670 million USD to 117,946 million USD over the five-year span. The data indicates asset base expansion with a temporary contraction in 2023.
- Stockholders’ Equity
- Reported stockholders’ equity showed substantial variation. The value increased significantly from 25,317 million USD in 2020 to 45,991 million USD in 2022, then unexpectedly fell to 37,581 million USD in 2023 before recovering to 46,313 million USD in 2024. Adjusted equity values followed a similar pattern but were consistently higher than reported equity by a small margin, reflecting inventory adjustment effects. The fluctuations suggest volatility in equity possibly influenced by earnings variations or other equity adjustments.
- Net Income Attributable to Merck & Co., Inc.
- Reported net income exhibited considerable volatility. It nearly doubled from 7,067 million USD in 2020 to 13,049 million USD in 2021 and further increased to 14,519 million USD in 2022. However, there was a dramatic decline in 2023 to 365 million USD, followed by a strong rebound to 17,117 million USD in 2024. Adjusted net income followed a similar pattern, but with slight differences in magnitude, indicating that the LIFO adjustments had somewhat mitigating effects. This pronounced volatility in net income warrants attention, possibly tied to extraordinary items or operational challenges in 2023.
Merck & Co. Inc., Financial Data: Reported vs. Adjusted
Adjusted Financial Ratios: LIFO vs. FIFO (Summary)
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
- Current Ratio
- The reported current ratio shows an overall improving trend, increasing from 1.02 in 2020 to 1.36 in 2024, despite a dip in 2023 to 1.25. The adjusted current ratio follows a similar pattern, with values slightly higher than the reported figures, indicating adjustment impacts are minimal but consistently positive. This suggests strengthening short-term liquidity over the period, with a minor temporary weakening in 2023.
- Net Profit Margin
- The reported net profit margin exhibits significant variability, starting at 14.72% in 2020, peaking at 26.79% in 2021, and remaining relatively stable in 2022. A sharp decline to 0.61% in 2023 marks a notable anomaly, followed by a substantial recovery to 26.68% in 2024. Adjusted net profit margin values mirror these fluctuations closely, with slightly higher margins confirming minor adjustment effects. The 2023 dip indicates a possible extraordinary event affecting profitability briefly.
- Total Asset Turnover
- The reported total asset turnover ratio shows moderate stability with a slight overall increase from 0.52 in 2020 to around 0.55 in 2024, indicating consistent asset usage efficiency. Adjusted figures are virtually identical to reported values, suggesting adjustments have negligible influence on this metric.
- Financial Leverage
- Reported financial leverage declines notably from 3.62 in 2020 to 2.37 in 2022, indicating a reduction in reliance on debt or equity leverage, followed by an increase to 2.84 in 2023 and a decrease again to 2.53 in 2024. Adjusted financial leverage values are marginally lower but follow the same trend. This pattern reflects fluctuations in the company’s capital structure management with a general trend towards lower leverage compared to 2020.
- Return on Equity (ROE)
- The reported ROE improves from 27.91% in 2020 to a peak of 34.17% in 2021, then decreases to 31.57% in 2022. There is a pronounced collapse to 0.97% in 2023, mirroring the net profit margin drop, before rebounding strongly to 36.96% in 2024. Adjusted ROE follows these shifts with slightly lower 2020 and 2021 values but a less severe decline in 2023 (1.66%) and a similar recovery in 2024. This suggests the company experienced a temporary but severe downturn in profitability impacting equity returns.
- Return on Assets (ROA)
- Reported ROA rises steadily from 7.72% in 2020 to 13.3% in 2022, falls sharply to 0.34% in 2023, then recovers to 14.62% in 2024. Adjusted ROA follows closely with relatively minor variances. This pattern aligns with the profit margin and ROE trends, confirming the temporary profit disruption in 2023 also impacted asset efficiency in generating returns.
Merck & Co. Inc., Financial Ratios: Reported vs. Adjusted
Adjusted Current Ratio
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
2024 Calculations
1 Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Adjusted current ratio = Adjusted current assets ÷ Current liabilities
= ÷ =
The financial data indicates an overall positive trend in both reported and inventory LIFO reserve adjusted current assets from 2020 to 2024. Reported current assets increased from $27,764 million in 2020 to $38,782 million in 2024, reflecting a substantial growth over the five-year period. Similarly, adjusted current assets, which account for inventory LIFO reserve adjustments, also exhibited an upward trajectory, rising from $27,846 million in 2020 to $39,622 million in 2024.
This consistent increase suggests an expansion in the company's short-term asset base, with the adjusted figures slightly higher than the reported ones each year, highlighting the effect of inventory valuation adjustments on current assets.
Regarding liquidity, the reported current ratio demonstrated improvement from 1.02 in 2020 to a peak of 1.47 in 2022, indicating strengthening short-term financial health with current assets more than sufficient to cover current liabilities. However, there was a decline to 1.25 in 2023, followed by a recovery to 1.36 in 2024, suggesting some fluctuation but maintaining a comfortable liquidity position overall.
The adjusted current ratio mirrors this pattern but consistently shows marginally higher values compared to the reported ratios. Starting at 1.02 in 2020, it rose to 1.49 in 2022, dipped slightly to 1.27 in 2023, then increased to 1.39 in 2024. The adjustment for LIFO reserve enhances the liquidity ratios, reflecting the impact of inventory adjustments on the company's liquidity assessment.
In summary, both the asset base and liquidity measures reveal strengthening financial conditions over the period, with minor fluctuations observed in 2023. The adjustments for inventory valuation modestly improve the presentation of current assets and liquidity ratios, emphasizing the importance of considering LIFO reserve effects in financial analysis.
Adjusted Net Profit Margin
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
2024 Calculations
1 Net profit margin = 100 × Net income attributable to Merck & Co., Inc. ÷ Sales
= 100 × ÷ =
2 Adjusted net profit margin = 100 × Adjusted net income attributable to Merck & Co., Inc. ÷ Sales
= 100 × ÷ =
- Net Income Trends
- The reported net income attributable to the company demonstrated a significant increase from 7,067 million US dollars in 2020 to 13,049 million US dollars in 2021. This upward trajectory continued in 2022, reaching 14,519 million US dollars. However, in 2023 there was a pronounced decline to 365 million US dollars, followed by a sharp recovery in 2024 with net income rising to 17,117 million US dollars. The adjusted net income followed a similar pattern, increasing steadily from 6,978 million US dollars in 2020 to 14,796 million US dollars in 2022, then dropping considerably to 634 million US dollars in 2023, and subsequently increasing to 17,395 million US dollars in 2024. The large dip observed in 2023 reflects an anomalous event or extraordinary adjustment impacting profitability for that year.
- Net Profit Margin Analysis
- The reported net profit margin showed a consistent improving trend from 14.72% in 2020 to 26.79% in 2021, followed by a slight decrease to 24.49% in 2022. A steep fall to 0.61% was recorded in 2023, mirroring the significant drop in reported net income. In 2024, the margin recovered markedly to 26.68%. The adjusted net profit margin exhibited a similar pattern, climbing from 14.54% in 2020 to 26.66% in 2021, then slightly increasing to 24.96% in 2022, before falling to 1.05% in 2023, and rising again to 27.11% in 2024. The adjustment consistently results in marginally lower but comparable profit margins, indicating that adjustments primarily affect absolute income levels without significantly distorting profitability ratios.
- Overall Observations
- The data reveals a general trend of strong profitability growth from 2020 to 2022, interrupted by a significant decline in 2023, which appears to be transient given the robust rebound in 2024. Both reported and adjusted figures reflect these fluctuations consistently. The concordance between reported and adjusted net profits and margins suggests reliable financial reporting practices, with adjustments having limited impact on the core profitability indicators. The steep decline in 2023 warrants further investigation to understand underlying causes such as one-time charges, impairments, or market disruptions.
Adjusted Total Asset Turnover
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
2024 Calculations
1 Total asset turnover = Sales ÷ Total assets
= ÷ =
2 Adjusted total asset turnover = Sales ÷ Adjusted total assets
= ÷ =
- Total Assets
- The reported total assets demonstrated an overall upward trend from 91,588 million US dollars in 2020 to 117,106 million US dollars in 2024. Despite a slight decrease observed in 2023 compared to 2022, total assets increased significantly over the five-year period. The adjusted total assets, which account for the inventory LIFO reserve, closely mirrored this trend, starting at 91,670 million US dollars in 2020 and reaching 117,946 million US dollars in 2024, indicating a consistent adjustment effect over time.
- Total Asset Turnover
- The reported total asset turnover fluctuated over the period, beginning at 0.52 in 2020, declining to a low of 0.46 in 2021, and subsequently recovering to peak at 0.56 in 2023 before slightly decreasing to 0.55 in 2024. The adjusted total asset turnover showed a similar pattern, with values starting at 0.52, dipping to 0.46, rising to 0.56, and finally settling at 0.54 in 2024. These fluctuations suggest variations in the company's efficiency in using its assets to generate revenue, with the highest efficiency observed around 2023.
- Comparison Between Reported and Adjusted Metrics
- The differences between reported and adjusted values for total assets and total asset turnover were minimal throughout the period. Adjusted total assets were consistently slightly higher than reported figures, reflecting the inventory LIFO reserve adjustment. Adjusted total asset turnover values were nearly identical to reported ones, indicating that the LIFO adjustment had a negligible impact on this efficiency ratio.
- Overall Insights
- The data illustrates steady asset growth accompanied by fluctuating asset utilization efficiency. The drop in asset turnover in 2021 suggests a period of lower asset efficiency which improved markedly by 2023. The minimal discrepancy between reported and adjusted figures implies that the LIFO reserve adjustment did not materially affect the financial metrics analyzed. The trends suggest a stable financial position with moderate variations in operational efficiency over the five-year span.
Adjusted Financial Leverage
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
2024 Calculations
1 Financial leverage = Total assets ÷ Total Merck & Co., Inc. stockholders’ equity
= ÷ =
2 Adjusted financial leverage = Adjusted total assets ÷ Adjusted total Merck & Co., Inc. stockholders’ equity
= ÷ =
- Total Assets
- The reported total assets exhibit a general upward trend over the five-year period, increasing from 91,588 million US dollars in 2020 to 117,106 million US dollars in 2024. There is a slight dip observed in 2023, where the reported assets decreased to 106,675 million from 109,160 million in the previous year. Adjusted total assets, which account for inventory LIFO reserve adjustments, closely follow the reported figures but consistently present marginally higher values. The adjustments slightly increase the asset base each year, reaching 117,946 million in 2024.
- Stockholders' Equity
- The reported stockholders’ equity shows significant volatility across the period. There is a notable increase from 25,317 million US dollars in 2020 to 38,184 million in 2021, continuing the upward trajectory to 45,991 million in 2022. However, in 2023, equity declines substantially to 37,581 million before recovering again to 46,313 million in 2024. The adjusted equity figures, which incorporate inventory adjustments, mirror this trend but are consistently marginally higher, peaking at 47,153 million in 2024. The fluctuations suggest variability in retained earnings, comprehensive income, or other equity components during the analyzed years.
- Financial Leverage Ratio
- The reported financial leverage ratio, defined as the ratio of total assets to stockholders' equity, decreases overall from 3.62 in 2020 to 2.53 in 2024, indicating a gradual reduction in the use of debt relative to equity over the period. A notable decrease occurs between 2020 and 2022, followed by a slight increase in 2023 before declining again in 2024. The adjusted financial leverage ratio closely tracks the reported values, maintaining a slightly lower level, reflecting the increased asset and equity base due to inventory adjustments. This trend suggests a modest improvement in the company’s capital structure, with equity growing at a faster pace than liabilities in most years.
Adjusted Return on Equity (ROE)
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
2024 Calculations
1 ROE = 100 × Net income attributable to Merck & Co., Inc. ÷ Total Merck & Co., Inc. stockholders’ equity
= 100 × ÷ =
2 Adjusted ROE = 100 × Adjusted net income attributable to Merck & Co., Inc. ÷ Adjusted total Merck & Co., Inc. stockholders’ equity
= 100 × ÷ =
- Net Income Trends
- The reported net income attributable to the company showed a strong upward trend from 2020 through 2022, increasing from $7,067 million to $14,519 million. However, there was a significant decline in 2023, with reported net income dropping sharply to $365 million. The figure rebounded considerably in 2024, reaching $17,117 million, the highest value in the observed period. The adjusted net income mirrored this pattern closely, increasing from $6,978 million in 2020 to $14,796 million in 2022, falling sharply to $634 million in 2023, and then rising even further to $17,395 million in 2024.
- Stockholders’ Equity Trends
- Reported total stockholders’ equity increased steadily from $25,317 million in 2020 to $45,991 million in 2022. However, it experienced a notable decrease in 2023 to $37,581 million before rising again to $46,313 million in 2024. The adjusted stockholders’ equity followed a similar trajectory, beginning at $25,399 million in 2020, increasing to $46,284 million in 2022, declining to $38,143 million in 2023, and then recovering to $47,153 million in 2024.
- Return on Equity (ROE) Patterns
- Reported ROE demonstrated an overall increasing trend from 27.91% in 2020 to 34.17% in 2021, peaking slightly lower at 31.57% in 2022. In 2023, there was a pronounced drop to 0.97%, reflecting the sharp decline in net income that year. ROE then surged to 36.96% in 2024, the period's highest rate. Adjusted ROE followed a comparable pattern, starting at 27.47% in 2020, modestly increasing to 33.99% in 2021, and 31.97% in 2022. The adjusted ROE fell to 1.66% in 2023 but then rose significantly to 36.89% in 2024.
- Overall Analysis
- The data indicate that financial performance, as measured by net income, stockholders’ equity, and ROE, generally improved through 2022, followed by an unexpected and substantial downturn in 2023 across all metrics. This downturn was short-lived, with a robust recovery evident in 2024. The adjusted figures closely align with reported data, suggesting inventory LIFO reserve adjustments have minimal impact on the overall trend interpretation. The volatility in 2023 may point to an extraordinary event or operational challenge affecting profitability and equity stability. Despite this, the company demonstrated resilience with strong recovery in 2024, reflected in net income surpassing prior peak levels and ROE reaching a new high.
Adjusted Return on Assets (ROA)
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
2024 Calculations
1 ROA = 100 × Net income attributable to Merck & Co., Inc. ÷ Total assets
= 100 × ÷ =
2 Adjusted ROA = 100 × Adjusted net income attributable to Merck & Co., Inc. ÷ Adjusted total assets
= 100 × ÷ =
The financial data reveal several notable trends and fluctuations over the five-year period under review. The reported net income attributable demonstrates significant variability, with a substantial increase from 7,067 million US dollars in 2020 to 13,049 million in 2021, followed by a further rise to 14,519 million in 2022. However, there is a pronounced decline in 2023, with net income falling sharply to 365 million, before rebounding strongly to 17,117 million in 2024.
The adjusted net income attributable exhibits a similar pattern, rising steadily from 6,978 million in 2020 to 12,984 million in 2021 and 14,796 million in 2022, dipping to 634 million in 2023, and recovering to 17,395 million in 2024. The adjusted figures are closely aligned with the reported ones, indicating consistent adjustments over time.
The reported total assets show a general upward trend, increasing from 91,588 million in 2020 to 105,694 million in 2021 and reaching 109,160 million in 2022. There is a slight decrease in 2023 to 106,675 million, followed by a rebound to 117,106 million in 2024. Adjusted total assets maintain a similar trajectory, with minor differences in magnitude, suggesting that inventory LIFO reserve adjustments slightly affect asset valuations but do not significantly alter overall trends.
Return on assets (ROA) based on reported data increases from 7.72% in 2020 to 12.35% in 2021 and 13.3% in 2022. The value plunges substantially to 0.34% in 2023, corresponding with the sharp drop in net income, before sharply rising to 14.62% in 2024. Adjusted ROA follows a comparable pattern, increasing from 7.61% in 2020 to 12.28% in 2021 and 13.52% in 2022, dropping to 0.59% in 2023, and recovering to 14.75% in 2024. The adjusted ROA is consistently slightly lower or higher than reported ROA, reflecting the impact of inventory adjustments on profitability measures.
Overall, the data highlight a period of strong income growth and asset expansion from 2020 through 2022, interrupted by a marked decline in profitability and net income in 2023. The recovery in 2024 is notable both in terms of income and efficiency as measured by ROA. The adjustments related to inventory LIFO reserve have a modest influence on asset values and profitability ratios, but the principal trends remain consistent between reported and adjusted figures.